Category: Cancer Types

Home / Cancer Types

Categories

March month is colorectal cancer awareness month

March 2023: In 2020, nearly 2 million cases of colorectal cancer will be diagnosed globally, making it the third most prevalent cancer type. It is the second leading cause of cancer-related deaths, a...

Peter MacCallum Cancer Centre and Cartherics will collaborate on ovarian cancer CAR-T cell therapy

March 2023: Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development programme agreement (CDPA) to develop CTH-002 for the treatmen...

New drug for primary bone cancer in children

March 2023: The scientists who developed a new drug that may be effective against all major types of primary bone cancer in children have called it "the most significant drug discovery in the field i...

KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA

SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previousl...

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening d...

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, CHINA, February 28, 2023 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherap...

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy p...

Enhertu has been approved in China for patients with HER2-positive metastatic breast cancer

Feb 2023: Enhertu (trastuzumab deruxtecan) from AstraZeneca and Daiichi Sankyo has been approved as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive br...

Actor Hamsa Nandini Provides an Update One Year After Breast Cancer Treatment

Feb 2023: Hamsa Nandini, who was diagnosed with Grade III Invasive Carcinoma (Breast Cancer) in 2021, has updated her Instagram followers on her health status. The actress, who has appeared in Telugu...

Novel treatment target for lymphoma patients who relapse after CAR-T therapy

Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prio...

Scan the code